Osteoprotegerin, but not osteopontin, as a potential predictor of vascular calcification in normotensive subjects

Stępień, Ewa; Fedak, Danuta; Klimeczek, Piotr; Wilkosz, Tadeusz; Banyś, Robert; Starzyk, Katarzyna; Bazanek, Marta; Pasowicz, Mieczysław

doi:10.1038/hr.2011.231

Cited by 17 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results support the results of an earlier study (8) in which increased serum OPG levels were associated with elevated CAC scores in asymptomatic individuals with type 2 diabetes. Our results are in agreement with several other studies that have shown an increase in serum OPG in association with vascular injury assessed by various methods in patients with and without type 2 diabetes (7, 26–28). The mechanisms for the increased serum OPG levels are, however, not clear.…”

Section: Discussionsupporting

confidence: 93%

Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes

et al. 2015

View full text Add to dashboard Cite

Objective Coronary artery calcification (CAC) is a prominent feature of atherosclerosis and is associated with cardiovascular events. In vitro studies have suggested that osteoprotegerin (OPG) and osteocalcin (OC) exert anticalcification potential in the vessel wall. The objective of this study was to investigate the association of CAC and serum bone biomarkers in persons with type 2 diabetes. Methods We examined 50 individuals with type 2 diabetes. CAC imaging was performed by multidetector computed tomography. CAC scores ≥10, expressed in Agatston units, were considered abnormal. OC, undercarboxylated OC (ucOC), and OPG levels were determined by enzyme-linked immunosorbent assay. Results Abnormal CAC scores were found for 64% of the study cohort. OPG levels were significantly elevated (5.5 ± 2.0 pmol/L vs. 4.2 ± 1.7 pmol/L; P = .026) for those with abnormal CAC scores. No univariate differences were found for OC or ucOC. Logistic regression analyses revealed that an increase in serum OPG level was significantly associated with an increase in CAC score (odds ratio, 3.324; 95% confidence interval, 1.321 to 8.359; P = .011). Longer duration of diabetes was a significant covariate (P = .026), whereas nonsignificant covariates in the final model were age, gender, systolic blood pressure, body mass index, insulin resistance determined by the homeostasis model assessment for insulin resistance, leptin, adiponectin, and glycemic control. The Nagelkerke R2 for the model was 0.66. Neither OC nor ucOC were significantly associated with elevated CAC scores. Conclusion Our results suggest that OPG is a more useful serum biomarker than OC or ucOC for identifying those at increased risk of arterial calcification in type 2 diabetes.

show abstract

Section: Discussionsupporting

confidence: 93%

Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Both Lp-PLA 2 and OPG promote plaque instability and rupture 4,8. The present finding is in line with recent histological evidence of significantly increased Lp-PLA 2 and OPG expression in carotid plaques in patients neurologically symptomatic during the preceding 1.5-4 months,4,8 and OPG prediction of premature atherosclerosis progression in asymptomatic normotensive individuals 24. Furthermore, the absence of a correlation between levels of Lp-PLA 2 and OPG ( r =-0.09, p =0.32) is consistent with their independent action in promoting plaque instability.…”

Section: Discussionsupporting

confidence: 91%

Multimarker Approach in Discriminating Patients with Symptomatic and Asymptomatic Atherosclerotic Carotid Artery Stenosis

et al. 2013

View full text Add to dashboard Cite

Background and PurposezzSeveral circulating biomarkers have been implicated in carotid atherosclerotic plaque rupture and thrombosis; however, their clinical utility remains unknown. The aim of this study was to determine the role of a large biomarker panel in the discrimination of symptomatic (S) vs. asymptomatic (A/S) subjects in a contemporary population with carotid artery stenosis (CS).MethodszzProspective sampling of circulating cytokines and blood lipids was performed in 300 unselected, consecutive patients with ≥50% CS, as assessed by duplex ultrasound (age 47-83 years; 110 with A/S and 190 with S) who were referred for potential CS revascularization.ResultszzCS severity and pharmacotherapy did not differ between the A/S and S patients. The median values of total cholesterol, low-density lipoprotein cholesterol, and lipoprotein(a) did not differ, but high-density lipoprotein (HDL) cholesterol was significantly higher (p<0.001) and triglycerides were lower (p=0.03) in the A/S-CS group than in the S-CS group. Interleukin-6 (IL-6) and high-sensitivity C-reactive protein were higher (p=0.04 and p=0.07, respectively) in the S-CS group. Circulating visfatin, soluble CD 40 receptor ligand, soluble vascular cell adhesion molecule, leptin, adiponectin, IL-1β, IL-8, IL-18, monocyte chemoattractant protein-1, myeloperoxidase, matrix metalloproteinases-8, -9, and -10, and fibrinogen were similar, but tissue inhibitor of matrix metalloproteinases-1 (TIMP) was reduced in S-CS compared to A/S-CS (p=0.02). Nevertheless, incorporation of TIMP and IL-6 did not improve the HDL-cholesterol receiver operating characteristics for S-CS status prediction. S-CS status was unrelated to angiographic stenosis severity or plaque burden, as assessed by intravascular ultrasound (p=0.16 and p=0.67, respectively). Multivariate logistic regression analysis revealed low HDL-cholesterol to be the only independent predictor of CS symptoms, with an odds ratio of 1.81 (95% confidence interval=1.15-2.84, p=0.01) for HDL <1.00 mmol/L (first quartile) vs. >1.37 (third quartile). In S-CS, osteoprotegerin and lipoprotein-associated phospholipase A2 (Lp-PLA 2 ) were elevated in those with recent vs. remote symptoms (p=0.01 and p=0.02, respectively).ConclusionszzIn an all-comer CS population on contemporary pharmacotherapy, low HDLcholesterol (but not other previously implicated or several novel circulating biomarkers) is an independent predictor of S-CS status. In addition, an increase in circulating osteoprotegerin and Lp-PLA2 may transiently indicate S transformation of the carotid atherosclerotic plaque.

show abstract

“…Numerous clinical studies have reported a consistent association between serum OPG levels and cardiovascular events and mortality, which suggests a role for OPG as a marker rather than a mediator of atherosclerosis and confirms previous in vivo studies [106,107,108,109,110]. …”

Section: Rankl Antagonistsupporting

confidence: 65%

Anti-Osteoporotic Drugs and Vascular Calcification: The Bidirectional Calcium Traffic

Yavropoulou¹,

Pikilidou

Yovos³

2013

J Vasc Res

View full text Add to dashboard Cite

During the last years, numerous epidemiological studies have demonstrated a direct relationship between vascular calcification and low bone mineral density. This observation is in line with experimental data demonstrating the osteogenic characteristics of calcified arteries. Various common risk factors have been suggested to link vascular calcification and bone loss, including aging, estrogen deficiency, vitamin D and K deficiency, diabetes mellitus, renal failure, smoking, chronic inflammation and oxidative stress. Although the underlying pathogenetic mechanisms are not yet clear, current research is focusing on anti-osteoporotic agents that could potentially affect the deposition of calcium in the arterial wall and thus provide an additional therapeutic strategy in elderly osteoporotic women prone to calcific cardiovascular disease.

show abstract

Osteoprotegerin, but not osteopontin, as a potential predictor of vascular calcification in normotensive subjects

Cited by 17 publications

References 38 publications

Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes

Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes

Multimarker Approach in Discriminating Patients with Symptomatic and Asymptomatic Atherosclerotic Carotid Artery Stenosis

Anti-Osteoporotic Drugs and Vascular Calcification: The Bidirectional Calcium Traffic

Contact Info

Product

Resources

About